A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis

DSpace Repository

A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis

Author: Bowlus, Christopher L.; Galambos, Michael R.; Aspinall, Richard J.; Hirschfield, Gideon M.; Jones, David E. J.; Doerffel, Yvonne; Gordon, Stuart C.; Harrison, Stephen A.; Kremer, Andreas E.; Mayo, Marlyn J.; Thuluvath, Paul J.; Levy, Cynthia; Swain, Mark G.; Neff, Guy W.; Sheridan, David A.; Stanca, Carmen M.; Berg, Christoph P.; Goel, Aparna; Shiffman, Mitchell L.; Vierling, John M.; Boudes, Pol; Steinberg, Alexandra; Choi, Yun-Jung; McWherter, Charles A.
Tübinger Autor(en):
Berg, Christoph Peter
Published in: Journal of Hepatology (2022), Bd. 77, H. 2, S. 353-364
Verlagsangabe: Elsevier
Language: English
Full text: http://dx.doi.org/10.1016/j.jhep.2022.02.033
ISSN: 0168-8278
DDC Classifikation: 610 - Medicine and health
Dokumentart: Article
Show full item record

This item appears in the following Collection(s)